BloodPressureHeartMeds.Org

Advaxis receives $244,479 QTDP credit for ADXS11-001 trial

November 15, 2017

The novel blood separation device work is being conducted in the laboratory of Dr. Michael R. King, a faculty member at the Department of Biomedical Engineering at Cornell University, Ithaca, NY. The study demonstrates that incorporation of the NaturalNano's HNT into the devices surface can improve targeting of CTC's. and enhance the natural rolling mechanism that Dr. King believes will allow them to be exposed to specific anti-cancer drugs or other therapeutic agents, or isolated for diagnostic and research purposes.  This cell separation device now in development by Dr. King has significant potential for a range of novel approaches to the treatment of cancer and other blood born diseases.   pubs.acs/doi/abs/10.1021/la101179y

Dr. Michael King, Associate Professor of Biomedical Engineering at Cornell University, said, "The ability to create stable coatings of Halloysite using an extremely thin layer of poly-L-lysine gives us a breakthrough, which will impact the diagnostic detection of circulating tumor cells in blood, and isolation for further use. An interesting result from their paper is that the Halloysite had no harmful effect on the cells enabling the delivery of live cells ready for treatment or analysis."

James Wemett, NaturalNano CEO, said "I am very excited to have this opportunity to have our Company's proprietary nanotubes incorporated into this promising device technology and featured in the presentation at AIChE's Annual Meeting."

Source: NaturalNano, Inc.